Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials

Diabetic Medicine : a Journal of the British Diabetic Association
Jaime A DavidsonLawrence A Leiter

Abstract

Both fasting (FPG) and postprandial plasma glucose (PPG) contribute to HbA1c levels. We investigated the relationship between achievement of American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) recommended FPG and/or PPG targets and glycaemic efficacy outcomes in two trials. In this post hoc analysis, data from participants with Type 2 diabetes in the phase 3 LixiLan-O (NCT02058147) and LixiLan-L (NCT02058160) trials were evaluated to compare the relationship between achievement of society-recommended FPG and/or PPG targets and efficacy (HbA1c change, HbA1c goal attainment, weight change) and safety outcomes in the treatment groups. Across treatment arms, iGlarLixi achieved the highest proportion of participants meeting both ADA- and AACE-recommended FPG and PPG targets at study end in both trials. A higher proportion of participants in the iGlarLixi (fixed-ratio combination of insulin glargine and lixisenatide) vs. insulin glargine alone or lixisenatide alone treatment arms achieved HbA1c goals (P < 0.001 for overall comparisons), irrespective of ADA- or AACE-defined targets. Hypoglycaemia rates [any, documented symptomatic (plasma glucose ≤ 3.9 mmol/l), and clinically important (pla...Continue Reading

References

Oct 27, 2004·Archives of Internal Medicine·Antonio CerielloJaakko Tuomilehto
Apr 22, 2006·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Louis Monnier, Claude Colette
Oct 25, 2006·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Peter N Båvenholm, Suad Efendic
Jun 18, 2011·Postgraduate Medicine·Thomas Blevins
Feb 21, 2013·Advances in Therapy·Michael HorowitzKaren L Jones
Feb 11, 2014·Diabetes Research and Clinical Practice
Apr 16, 2014·The Lancet. Diabetes & Endocrinology·André J Scheen, Luc F Van Gaal
Sep 29, 2015·Archives of public health = Archives belges de santé publique·Ezra Belay Ketema, Kelemu Tilahun Kibret
Aug 31, 2016·Diabetes Spectrum : a Publication of the American Diabetes Association·Sarah L Anderson, Jennifer M Trujillo
Jul 20, 2017·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Virginia ValentineJay H Shubrook
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Jan 26, 2018·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Alan J GarberGuillermo E Umpierrez
Apr 25, 2018·Clinical Diabetes : a Publication of the American Diabetes Association·Vanita R ArodaAnthony J Cannon

❮ Previous
Next ❯

Citations

Apr 1, 2020·Journal of Clinical Medicine·Angelo Maria PattiFerdinando Mannello

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02058147
NCT02058160

Software Mentioned

iGlar
iGlarLixi

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.